In this study, a total of 763 patients with PD-L1-positive (CPS ≥ 1) advanced gastric or GEJ adenocarcinoma were randomly assigned between three groups: pembrolizumab monotherapy, pembrolizumab combined with chemotherapy, or chemotherapy alone. The gene discussed is CD274; the disease is gastroesophageal junction adenocarcinoma.